Study Overview
Sex: All
Age: 18 Years and older (Adult, Older Adult)
No Study Documents
Study Overview
Sex: All
Age: 18 Years and older (Adult, Older Adult)
No Study Documents
BGB-3111_BGB-A317_Study_001
Completed
Zanubrutinib (BGB-3111) in Combination With Tislelizumab (BGB-A317) in Participants With B-cell Malignancies
Beigene Study ID
BGB-3111_BGB-A317_Study_001
ClinicalTrials.gov ID
China Drug Trials ID
CTR20180193
Sex: All
Age: 18 Years and older (Adult, Older Adult)
No Study Documents
Sex: All
Age: 18 Years and older (Adult, Older Adult)
No Study Documents